Abstracts tagged "risk assessment"

Abstract Number: 1249 • ACR Convergence 2022
Short-term Variations in Subchondral Tibial Bone Texture of Conventional X-Rays Predicts Knee Osteoarthritis Progression
Ahmad Almhdie-Imjabbar¹, Hechmi TOUMI², Zineb ZERZOUF³ and Eric LESPESSAILLES⁴, ¹University of Orleans / CHR Orleans, France, Orleans, Centre, France, ²Regional hospital centre of Orleans, France, Orleans, France, ³University of Tours, Tours, France, ⁴Regional hospital centre of Orleans, France, ORLEANS, Centre, France
Background/Purpose: Early detection and assessment of Knee Osteoarthritis (KOA) prognostic factors are crucial for developing management and treatments that aim at prevention of irreversible damage…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: 0285 • ACR Convergence 2021
Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
Reinder Raadsen¹, Romy Hansildaar¹, Maaike Heslinga², Arno van Kuijk¹ and Michael Nurmohamed³, ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of developing, mainly ischemic cardiovascular diseases (CVD). This is partly explained by…
Abstract Number: 0324 • ACR Convergence 2021
Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World
Bruno Teixeira, David Bell, Tim Holbrook and Ben Hoskin, Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Around 40-70% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN). LN is often underdiagnosed and early diagnosis is crucial for reducing…
Abstract Number: 0388 • ACR Convergence 2021
Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
Ariane Barbacki¹, Ada Man², Mianbo Wang³, Dylan Johnson⁴, Yuqing Zhang⁵, Mandana Nikpour⁶ and Murray Baron⁷, ¹McGill University, Montral, Montréal, QC, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Lady Davis institute for Medical Research, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Massachusetts General Hospital, Quincy, MA, ⁶University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁷Jewish General Hospital, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…
Abstract Number: 0517 • ACR Convergence 2021
TPMT and NUDT15 Genotype and Azathioprine Myelotoxicity in Patients with Inflammatory Conditions: Results from Real-World Clinical Practice
Alyson Dickson¹, Laura Daniel², Jacy Zanussi¹, Wei-Qi Wei¹, Dale Plummer¹, William Dupont³, Ge Liu¹, Prathima Anandi¹, Tyler Reese⁴, Kelly Birdwell¹, Vivian Kawai⁵, Adriana Hung¹, Qiping Feng¹, Nancy J. Cox¹, C. Michael Stein¹ and Cecilia Chung¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Pegram, TN, ³Vanderbilt University, Nashville, TN, ⁴Vanderbilt University Medical Center, Madison, TN, ⁵Vanderbilt Universty Medical Center, Nashville, TN
Background/Purpose: Azathioprine is frequently used for the treatment of several inflammatory conditions. However, treatment is often limited by adverse events, in particular myelotoxicity. Both thiopurine-S-methyltransferase…
Abstract Number: 0563 • ACR Convergence 2021
Validating the FRAX Score in a US Population-Based Study of Patients with Rheumatoid Arthritis
Madeline Peterson¹, Cynthia Crowson², Elena Myasoedova¹, Shreyasee Amin¹, John Davis¹, Sara Achenbach¹, Sundeep Kholsa¹ and Elizabeth Atkinson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: The FRAX tool, launched by the World Health Organization Collaborating Centre at the University of Sheffield in 2008 (https://www.sheffield.ac.uk/FRAX/), is widely used to quickly…
Abstract Number: 0645 • ACR Convergence 2021
Time Burden of QTc Screening for HCQ Users at a Single VA Rheumatology Clinic
Iziegbe Ehiorobo¹, Anna Montgomery² and Gabriela Schmajuk¹, ¹University of California San Francisco, San Francisco, CA, ²Department of Veterans Affairs, Tiburon, CA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in the treatment of rheumatic diseases. New guidance from the ACR supports routine monitoring of the QT…
Abstract Number: 0648 • ACR Convergence 2021
Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative
Beth Rutstein¹, Melissa Argraves², Atiye Bilgic Dagci², Sarah Bayefsky², Julia Rood², Julie Chase³, Jay Mehta², Melissa Lerman², Cory Stingl⁴ and Jon Burnham², ¹Children's Hospital of Philadelphia, Wynnewood, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Durham, NC
Background/Purpose: Hypogammaglobulinemia following rituximab therapy is a potentially severe complication that can lead to infection-related morbidity and mortality. If recognized, clinicians may prevent infections by…
Abstract Number: 1054 • ACR Convergence 2021
Metabolomics as an Innovative Tool for Cardiac Risk Stratification in Patients with Rheumatic Diseases: Results from a Pilot Study
Sorwe Mojtahed Poor¹, Lisa Hahnefeld², Frank Behrens³, Harald Burkhardt⁴, Michaela Köhm⁵, Geisslinger Gerd⁶ and Gurke Robert⁷, ¹University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ²pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany, Frankfurt, Germany, ³Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, ⁴University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ⁵University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ⁶Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ⁷pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany
Background/Purpose: Patients with rheumatic diseases (RMD) face an increased cardiovascular (CV) mortality compared to the general population. Still, risk stratification based on traditional cardiovascular risk…
Abstract Number: 1135 • ACR Convergence 2021
Osteoporosis Assessment and Outcomes in Candidates for Liver Transplantation in a Tertiary Center
Cristina Rodríguez-Alvear¹, MARIANO ANDRES¹, Maria-Luisa Peral-Garrido², Irene Calabuig³, Ernesto Tovar-Sugrañes¹, Mari-Carmen López-González¹, Pilar Bernabeu¹, Agustín Martínez-Sanchis¹, Ximo Esteve¹, Paloma Vela¹, Cayetano Miralles¹ and Maria Vega Jovani Casano⁴, ¹Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Novelda, Spain, ³Hospital General Universitario de Alicante, Alicante, Spain, ⁴National Health system, Alicante, Spain
Background/Purpose: A rapid loss of bone mass and an increase in fractures have been described in the first six months after liver transplantation. This phenomenon…
Abstract Number: 1142 • ACR Convergence 2021
For Vulnerable Population Treated at a Community Health Center (CHC), Primary Care Physician (PCP) Turnover Should Be Included in Social Determinants of Health (SDH) on Non-completing Osteoporosis Treatment
Yu Na Kim¹ and Julie Crosson², ¹DotHouse Health, Boston, ²DotHouse Health, Boston University, Boston
Background/Purpose: Unexplained interruptions in treatment are common among patients with osteoporosis, but it is not well studied how PCP turnover affects incompletion of osteoporosis treatment…
Abstract Number: 1423 • ACR Convergence 2021
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Melissa Munroe¹, Rufei Lu², Timothy Gross¹, George Tsokos³, Michael Keith⁴, John Harley⁵ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, OUHSC, Oklahoma City, OK, ³BIDMC, Boston, MA, ⁴Inova, Arlington, VA, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: SLE is a chronic autoimmune disease driven by immune dysregulation. We have previously identified patterns of disordered immunity present prior to and concurrent with…
Abstract Number: 1527 • ACR Convergence 2021
Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis
Michael Macklin¹, Chester Oddis², Siamak Moghadam-Kia², Dana Ascherman² and Rohit Aggarwal², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rituximab is an anti-CD20 antibody with therapeutic use in myositis. However, given its B cell depleting mechanism, there is concern regarding its association with…
Abstract Number: 1528 • ACR Convergence 2021
Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
William West¹, Therese Posas-Mendoza², Jerald Zakem³, William Davis¹ and Robert Quinet⁴, ¹Ochsner Medical Center, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, LA, ³Ochsner Health Systems, Metairie, LA, ⁴Ochsner Health, River Ridge, LA
Background/Purpose: Intravenous immunoglobulin (IVIG) is a blood product created by pooling of donor plasma that is used for a wide range of indications. IVIG is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].